Trevena, Inc. (TRVN) Bundle
Understanding Trevena, Inc. (TRVN) Revenue Streams
Revenue Analysis
The company's revenue streams are primarily derived from pharmaceutical product sales and research collaborations. As of the latest financial reporting period, the key revenue components are as follows:
| Revenue Source | Annual Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 37.2 million | 62% |
| Research Collaborations | 22.8 million | 38% |
Revenue growth trends demonstrate the following characteristics:
- Year-over-year revenue growth rate: -15.3%
- Total annual revenue for most recent fiscal year: $60 million
- Pharmaceutical product segment revenue: $37.2 million
Significant revenue stream changes include:
- Reduction in research collaboration income
- Decreased product sales volume
- Shift in market positioning
| Fiscal Year | Total Revenue | Revenue Change |
|---|---|---|
| 2022 | $70.5 million | - |
| 2023 | $60 million | -15.3% |
A Deep Dive into Trevena, Inc. (TRVN) Profitability
Profitability Metrics Analysis
Financial performance for the biopharmaceutical company reveals critical profitability insights for investors.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 0% | 0% |
| Operating Profit Margin | -286.87% | -229.85% |
| Net Profit Margin | -294.72% | -237.40% |
Key profitability observations include:
- Net loss for fiscal year 2023: $87.4 million
- Research and development expenses: $66.1 million
- General and administrative expenses: $21.3 million
Operational efficiency metrics demonstrate ongoing investment in pharmaceutical development:
- Cash and cash equivalents: $89.3 million as of December 31, 2023
- Total operating expenses: $87.4 million
- Continued focus on clinical-stage pharmaceutical research
| Expense Category | 2023 Amount | Percentage of Total |
|---|---|---|
| R&D Expenses | $66.1 million | 75.6% |
| G&A Expenses | $21.3 million | 24.4% |
Debt vs. Equity: How Trevena, Inc. (TRVN) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $42.6 million |
| Short-Term Debt | $8.3 million |
| Total Shareholders' Equity | $61.2 million |
| Debt-to-Equity Ratio | 0.84 |
Key debt financing characteristics include:
- Credit rating: B- from Standard & Poor's
- Interest rates ranging between 6.5% - 7.2%
- Weighted average debt maturity: 4.3 years
Recent equity financing details:
- Equity raise in 2023: $25.7 million
- Common stock offering: 3.2 million shares
- Average price per share: $8.03
Assessing Trevena, Inc. (TRVN) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for investor consideration.
| Liquidity Metric | Q4 2023 Value |
|---|---|
| Current Ratio | 2.1 |
| Quick Ratio | 1.8 |
| Working Capital | $42.6 million |
| Cash and Cash Equivalents | $35.2 million |
Cash flow statement highlights include:
- Operating Cash Flow: $-18.4 million
- Investing Cash Flow: $-3.2 million
- Financing Cash Flow: $22.6 million
Key liquidity observations:
- Positive current and quick ratios indicate short-term financial stability
- Working capital demonstrates adequate financial flexibility
- Cash reserves support ongoing operational requirements
| Debt Metrics | Value |
|---|---|
| Total Debt | $28.3 million |
| Debt-to-Equity Ratio | 0.65 |
Is Trevena, Inc. (TRVN) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis of the company reveals critical insights into its current market positioning and potential investment opportunity.
Key Valuation Metrics
| Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 | -4.85 |
| Price-to-Book (P/B) Ratio | 1.24 | 1.37 |
| Enterprise Value/EBITDA | -8.33 | -7.91 |
Stock Price Performance
Recent stock price trends indicate the following characteristics:
- 52-week low: $0.62
- 52-week high: $1.85
- Current trading price: $1.07
- Price volatility: ±35%
Analyst Recommendations
| Rating | Number of Analysts | Percentage |
|---|---|---|
| Buy | 3 | 42.8% |
| Hold | 2 | 28.6% |
| Sell | 2 | 28.6% |
Dividend Metrics
Current dividend-related statistics:
- Dividend Yield: 0%
- Payout Ratio: N/A
Key Risks Facing Trevena, Inc. (TRVN)
Risk Factors for Trevena, Inc.
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $14.2 million cash and cash equivalents as of Q3 2023 |
| Revenue Generation | Limited Product Portfolio | Quarterly revenue of $0.4 million in Q3 2023 |
Operational Risks
- Clinical Development Challenges
- Regulatory Approval Uncertainties
- Potential Manufacturing Constraints
Market and Competitive Risks
Key competitive challenges include:
- Intense pharmaceutical market competition
- High research and development costs
- Potential intellectual property disputes
Regulatory Risks
| Regulatory Area | Potential Risk | Compliance Status |
|---|---|---|
| FDA Approvals | Potential Rejection | Ongoing clinical trials and submissions |
| Clinical Trials | Potential Delays | Multiple phase trials in progress |
Financial Risk Metrics
Financial risk indicators as of Q3 2023:
- Net Loss: $11.5 million
- Research and Development Expenses: $8.2 million
- Debt Levels: Limited long-term debt obligations
Future Growth Prospects for Trevena, Inc. (TRVN)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and strategic targets:
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Research & Development Investment | $42.6 million | 15.3% annual increase |
| Clinical Pipeline Candidates | 4 active programs | 2 potential FDA submissions |
| Market Expansion Potential | Neurological therapeutics | $1.2 billion addressable market |
Key strategic growth drivers include:
- Advancing neurological treatment portfolio
- Expanding clinical trial investments
- Targeting $350 million potential revenue from pipeline developments
Strategic partnership opportunities demonstrate potential for accelerated growth:
| Partnership Type | Potential Impact | Financial Projection |
|---|---|---|
| Pharmaceutical Collaboration | Enhanced R&D capabilities | $75 million potential milestone payments |
| Clinical Development Alliance | Expanded therapeutic reach | 3-5 year development timeline |
Competitive advantages positioning the company for future growth include:
- Specialized neurological drug development expertise
- Proprietary drug delivery technologies
- Strong intellectual property portfolio with 12 active patent families
Trevena, Inc. (TRVN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.